Disease · MONDO_0006951
retinal vein occlusion
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. retinal vein occlusion. Diseases, record MONDO_0006951. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006951
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 2 of its 28 drugs, from EMA Human Drugs and PMDA
- Open Targets
Drugs28
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Approval | EMA Human Drugs | 27 | 25 | 24 | Drugs and targets |
| AFLIBERCEPT | CHEMBL1742982 | Protein | Approval | EMA Human Drugs and PMDA | 28 | 13 | 12 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 12 | 12 | 11 | Drugs and targets |
| TRIAMCINOLONE ACETONIDE | CHEMBL1504 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 6 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CONBERCEPT | CHEMBL2108313 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| FARICIMAB | CHEMBL4297750 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PARNAPARIN | CHEMBL3707207 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 28
See all 28 drugsTargets69
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 6 | Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor | Approval | https://conductscience.org/library/genes/7422 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CSF1R | Macrophage colony-stimulating factor 1 receptor | 2 | Macrophage colony stimulating factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/1436 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 2 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 2 | https://conductscience.org/library/genes/2322 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 2 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 2 | Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5156 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 2 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
1 to 10 of 69
See all 69 targetsTrials61
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04740905 | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion | Phase 3 | 553 | 2024-01-18 | Macular Edema, Branch Retinal Vein Occlusion | FARICIMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02980874 | Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO | Phase 3 | 460 | 2021-04-14 | Macular Edema, Retinal Vein Occlusion | AFLIBERCEPT, TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01599650 | Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion | Phase 3 | 455 | 2016-11-10 | Branch Retinal Vein Occlusion | RANIBIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01969708 | Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) | Phase 3 | 362 | 2018-08-21 | Central Retinal Vein Occlusion | AFLIBERCEPT, BEVACIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03203447 | Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO | Phase 3 | 325 | 2021-04-23 | Macular Edema, Retinal Vein Occlusion | BEVACIZUMAB, RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01918371 | A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema | 323 | 2016-05-26 | Retinal Vein Occlusion, Macular Edema | AFLIBERCEPT, BEVACIZUMAB, RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01396057 | Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) | Phase 3 | 244 | 2014-07-16 | Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion | DEXAMETHASONE, RANIBIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01521559 | Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) | Phase 3 | 183 | 2014-11-13 | Branch Retinal Vein Occlusion | AFLIBERCEPT | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02800642 | Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO | Phase 4 | 162 | 2020-07-08 | Central Retinal Vein Occlusion | AFLIBERCEPT | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01805323 | A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema | 101 | 2014-05-30 | Macular Edema | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 61
See all 61 trialsComparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Active vs Control: Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) | 114 of 231 | 127 of 229 | 460 | NCT02980874 | Trial comparisons |
| Active vs Control: deaths from any cause | 0 of 231 | 0 of 229 | 460 | NCT02980874 | Trial comparisons |
| Active vs Control: serious adverse events | 25 of 231 | 28 of 229 | 460 | NCT02980874 | Trial comparisons |
| Aflibercept vs Bevacizumab: deaths from any cause | 1 of 180 | 1 of 182 | 362 | NCT01969708 | Trial comparisons |
| Aflibercept vs Bevacizumab: serious adverse events | 14 of 180 | 14 of 182 | 362 | NCT01969708 | Trial comparisons |
| Active vs Control: Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) | 64 of 162 | 76 of 163 | 325 | NCT03203447 | Trial comparisons |
| Active vs Control: deaths from any cause | 0 of 160 | 0 of 162 | 322 | NCT03203447 | Trial comparisons |
| Active vs Control: serious adverse events | 1 of 160 | 3 of 162 | 322 | NCT03203447 | Trial comparisons |
| Patients With RVO vs Patients With DME: serious adverse events | 12 of 165 | 12 of 156 | 321 | NCT01918371 | Trial comparisons |
| Ranibizumab vs Dexamethasone: Rate of the Internal Ocular Pressure (IOP) | 79 of 126 | 106 of 118 | 244 | NCT01396057 | Trial comparisons |
1 to 10 of 20
See all 20 comparisons in its trialsPapers from its trials31
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006951
GET https://conductscience.org/api/diseases/v1/MONDO_0006951/drugs?page=2